Active Biotech AB Interim Report January - September 2010

October 27, 2010 08:30 (CEST)

  • Laquinimod ― Phase III trials proceeding as planned, results from Phase II extension study published in scientific journal
  • TASQ ― preparations ongoing for start of Phase III in first half of 2011
  • ANYARA ― ongoing phase III trial expected to be concluded in first half of 2012
  • 57-57 ― exploratory SLE clinical trial completed
  • ISI ― project continuing according to plan
  • RhuDex(TM) ― preparations for continued clinical development in progress
  • Net sales of SEK 8.5 M (7.7)
  • Operating loss of SEK 149.7 M (loss: 164.6)
  • Loss after tax SEK 156.8 M (loss: 165.1)
  • Loss per share for the period amounted to SEK 2.40 (loss: 2.90)

 

For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95

 

Göran Forsberg                                   
VP Investor Relations & Business Development                          
Tel: +46 (0)46-19 11 54                                        

 

Hans Kolam                                                                         
CFO                                                                       
Tel: +46 (0)46-19 20 44

 

Active Biotech AB
(Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00                                                        

 

 

This report is also available at www.activebiotech.com           

 

                

Active Biotech AB Interim Report January-September 2010